Back to overview
Back to overview

Primary results from the SAUL study

Prof. Jens Bedke (DE) and Prof. Maria José Ribal discussed the primary results from the SAUL study with Prof. Axel Merseburger (DE). SAUL is a prospective multinational single-arm study of atezolizumab (atezo) for locally advanced or metastatic urothelial carcinoma (UC) or non-UC of the urinary tract.

Read the written report about the study here.

Categories

09 April 2024

Highlights from Day 4 at EAU24

Below are some highlights from the last day of EAU24, including session reports, a webcast, and a new episode of
08 April 2024

Urothelial cancer: Practice-changing results

Why is there no added benefit to extended pelvic lymph node dissection (ePLND)? The Plenary Session on day 4 of